Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration

Journal of Infectious Diseases

Volumn 207, Issue 2, 2013, Pages 213-222

  Azzoni, Livio ^a   Foulkes, Andrea S ^b   Papasavvas, Emmanouil ^a   Mexas, Angela M ^c   Lynn, Kenneth M ^a,c   Mounzer, Karam ^d   Tebas, Pablo ^c   Jacobson, Jeffrey M ^e   Frank, Ian ^c   Busch, Michael P ^f,g   Deeks, Steven G ^g   Carrington, Mary ^h,i   O'Doherty, Una ^c   Kostman, Jay ^c   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Philadelphia Fight   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

HIV 1; immunotherapy; interferon alpha; viral integration

Indexed keywords

ANTIRETROVIRUS AGENT; DNA; INTERLEUKIN 28; PEGINTERFERON ALPHA2A; VIRUS DNA; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DNA INTEGRATION; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LABORATORY TEST; LATENT VIRUS INFECTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 84871797372     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis663     Document Type: Article

References (43)

1. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-8.
2. Wilen CB, Wang J, Tilton JC, et al. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 2011; 7:e1002020.
3. Angel JB, Routy JP, Tremblay C, et al. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS 2011; 25:731-9.
4. Henry K, Katzenstein D, Cherng DW, et al. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/-interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr 2006; 42:140-8.
5. Matalon S, Rasmussen TA, Dinarello CA. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 2011; 17:466-72.
6. Chang JJ, Altfeld M. Innate immune activation in primary HIV-1 infection. J Infect Dis 2011; 202(Suppl. 2):S297-301.
7. Rotger M, Dang KK, Fellay J, et al. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog 2010; 6:e1000781.
8. Chehimi J, Papasavvas E, Tomescu C, et al. Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand. J Virol 2010; 84:2762-73.
9. Tomescu C, Chehimi J, Maino VC, Montaner LJ. NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. J Immunol 2007; 179:2097-104.
10. Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008; 126:235-42.
11. Lane HC, Kovacs JA, Feinberg J, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 1988; 2: 1218-22.
12. Boue F, Reynes J, Rouzioux C, et al. Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. AIDS 2011; 25:115-8.
13. Dianzani F, Rozera G, Abbate I, et al. Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. J Interferon Cytokine Res 2008; 28:1-3.
14. Asmuth DM, Murphy RL, Rosenkranz SL, et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis 2010; 201:1686-96.
15. Linnen JM, Gilker JM, Menez A, et al. Sensitive detection of genetic variants of HIV-1 and HCV with an HIV-1/HCV assay based on transcription- mediated amplification. J Virol Methods 2002; 102:139-55.
16. Hatano H, Delwart EL, Norris PJ, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009; 83:329-35.
17. Hatano H, Delwart EL, Norris PJ, et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 2010; 24:2535-9.
18. Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011; 7: e1001300.
19. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
20. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
21. Papasavvas E, Kostman JR, Mounzer K, et al. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004; 1:e64.
22. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 1999; 96:15109-14.
23. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817-29.
24. Bashirova AA, Thomas R, Carrington M. HLA/KIR restraint of HIV: surviving the fittest. Annu Rev Immunol 2011; 29:295-317.
25. McMichael AJ, Jones EY. First-class control of HIV-1. Science 2010; 330:1488-90.
26. Thomas R, Apps R, Qi Y, et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009; 41:1290-4.
27. Poropatich K, Sullivan DJ Jr. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. The Journal of General Virology 2011; 92:247-68.
28. Kaur G, Mehra N. Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. Tissue Antigens 2009; 74:373-85.
29. Leslie A, Matthews PC, Listgarten J, et al. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol 2010; 84:9879-88.
30. Roland ME, Elbeik TA, Kahn JO, et al. HIV RNA testing in the context of nonoccupational postexposure prophylaxis. J Infect Dis 2004; 190:598-604.
31. Pillai SK, Abdel-Mohsen M, Guatelli J, et al. Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A 2012; 109:3035-40.
32. Goujon C, Malim MH. Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol 2010; 84:9254-66.
33. Guillot B, Portales P, Thanh AD, et al. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br J Dermatol 2005; 152:690-6.
34. Portales P, Reynes J, Pinet V, et al. Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo. Aids 2003; 17:495-504.
35. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193-7.
36. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998; 95:8869-73.
37. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29:1009-21.
38. Soumelis V, Scott I, Gheyas F, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98:906-12.
39. Machmach K, Leal M, Gras C, et al. Plasmacytoid dendritic cells reduce HIV production in Elite controllers. J Virol 2012; 86: 4245-52.
40. Autran B, Murphy RL, Costagliola D, et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008; 22:1313-22.
41. Kilby JM, Bucy RP, Mildvan D, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis 2006; 194:1672-6.
42. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 1999; 13:677-83.
43. Steingrover R, Pogany K, Fernandez Garcia E, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008; 22:1583-8.